A selection of major announcements

1. China Mobile: Profit attributable to shareholders in the first three quarters was 105.5 billion yuan, up 7.1% year on year

$CHINA MOBILE (00941.HK)$The Group's unaudited performance and operating data for the first three quarters of 2023 were released. Operating revenue for the first three quarters was RMB 775.6 billion, up 7.2% year on year; EBITDA was RMB 268.5 billion, up 6.7% year on year; profit attributable to shareholders was RMB 105.5 billion, up 7.1% year on year; the number of mobile customers was 990 million, of which the number of 5G package customers was 750 million; and the number of wired broadband customers was 295 million.

2. China Telecom: Profit attributable to shareholders for the first three quarters was 27.101 billion yuan, an increase of 10.4% over the previous year

$CHINA TELECOM (00728.HK)$It was announced that in the first three quarters of 2023, the company's operating revenue was RMB 384.254 billion, up 6.4% from the same period last year; of these, service revenue was RMB 349.743 billion, up 6.4% from the same period last year; EBITDA was RMB 105.648 billion, up 5.2% from the same period last year; profit attributable to the company's shareholders was RMB 27.101 billion, up 10.4% from the same period last year.

3. ZTE: Realized net profit of 7.84 billion yuan in the first three quarters, an increase of 14.97% over the previous year

$ZTE (00763.HK)$According to the third quarterly report, the company achieved operating income of 89.39 billion yuan, up 3.42% year on year; achieved net profit of 7.84 billion yuan, up 14.97% year on year; net profit after deducting non-return income of 7.10 billion yuan, up 27.93% year on year; net operating cash flow reached 9.26 billion yuan, up 148.78% year on year.

4. Huazhu Group-S: Average rentable room revenue in the third quarter recovered to 129% of 2019 levels

$HWORLD-S (01179.HK)$It was announced that Legacy-Huazhu's average rentable room revenue for the third quarter recovered to 129% of 2019 levels, with July-September returning to 132%, 128%, and 128% of 2019 levels, respectively. In the third quarter, the total number of newly opened hotels reached 545, while the number of closed hotels was 139. Furthermore, the average rentable room revenue of the “Legacy-DH” business has recovered to 107% of 2019 levels.

5. Tsingtao Brewery Co., Ltd.: The batch of malt covered by the media report has all been sealed. Currently, all production and operation conditions are normal

$TSINGTAO BREW (00168.HK)$It was announced that the company recently paid attention to media reports on Tsingtao Brewery No. 3. The relevant matters are now explained. Regarding the relevant media reports, the company attached great importance to them and alerted the public security authorities as soon as possible. The public security authorities have already intervened in the investigation. This batch of malt has been completely sealed. The company also explained the situation on Tsingtao Brewery's official Weibo account. At present, the company's production and operation conditions are all normal!

IPO

$UBOX ONLINE (02429.HK)$The offer price is HK$9.4-11.4 per share from October 24 to 24

Earnings Report

$CHINA MOBILE (00941.HK)$Profit attributable to shareholders for the first three quarters was 105.5 billion yuan, an increase of 7.1% over the previous year

$CHINA TELECOM (00728.HK)$Profit attributable to shareholders for the first three quarters was 27.101 billion yuan, an increase of 10.4% over the previous year

$CIMC (02039.HK)$: Net profit attributable to shareholders for the first three quarters was 42-600 million yuan, a year-on-year decrease of 81% -87%

$ZTE (00763.HK)$Net profit for the first three quarters was 7.84 billion yuan, an increase of 14.97% over the previous year

Operational data

$CHINA RE (01508.HK)$: Dadi Financial Insurance's original total premium income from January to September was approximately RMB 38.946 billion

$CHI MER LAND (00978.HK)$Total contract sales for the first three quarters were about 26.653 billion yuan, a year-on-year decrease of about 20.7%

$CHINA COMM CONS (01800.HK)$The amount of new contracts signed from January to September was 1171,744 billion yuan, an increase of 13.52% over the previous year

$SHENZHEN INVEST (00604.HK)$: January-September total contract sales were 19.131 billion yuan, up 171.1% year on year

$SINOPEC SEG (02386.HK)$The total value of new contracts signed in the third quarter was 6.627 billion yuan

$DYNAGREEN ENV (01330.HK)$The cumulative power generation for the first three quarters was 3.46 billion kilowatts, an increase of 10.61% over the previous year

$HWORLD-S (01179.HK)$: Average rentable room revenue in the third quarter recovered to 129% of 2019 levels

$CHINA DONGXIANG (03818.HK)$: In the first half of the fiscal year, retail sales of Kappa brand stores recorded a high single-unit increase year over year

Company matters

$HENLIUS (02696.HK)$: Obtained Brazilian GMP certificate

$HANSOH PHARMA (03692.HK)$Conclude a license agreement with GSK

$TSINGTAO BREW (00168.HK)$: The batch of malt covered by the media report has all been sealed. Currently, all production and operation conditions are normal

$BEIGENE (06160.HK)$: The National Institute of Health and Clinical Optimization of the United Kingdom recommends Baiyueze® for the treatment of adult patients with chronic lymphocytic leukemia

$FUDANZHANGJIANG (01349.HK)$: Injectable FZ-AD005 Antibody Binder for Treatment of Advanced Solid Tumors Obtaining Drug Clinical Trial Application Notice

$JACOBIO-B (01167.HK)$Clinical data on the combined use of Glarese and JAB-3312 will be announced at the 2023 ESMO Annual Meeting

$TRANSCENTA-B (06628.HK)$: In 2023, ESMO will announce updated efficacy data of osemitab (TST001) combined with CAPOX for first-line treatment of gastric or gastroesophageal junction adenocarcinoma

$ASCENTAGE-B (06855.HK)$The latest data on APG-1252 combined with ositinib for the treatment of non-small cell lung was presented at the 2023 European Society of Internal Oncology (ESMO) Annual Meeting

$SKB BIO-B (06990.HK)$: MSD decided to terminate the company's exclusive license to develop, manufacture, and commercialize a pre-clinical ADC asset, and resumed trading on October 24

Equity incentives

$XPENG-W (09868.HK)$A total of 4.694,000 restricted share units were granted

$SMOORE INTL (06969.HK)$A total of 1.56 million share options were granted

$SMOORE INTL (06969.HK)$A total of 648,500 bonus shares were awarded

$TONGCHENGTRAVEL (00780.HK)$Grant of 277.299 million share options and 277.299 million restricted share units

Repurchase cancellation

$AIA (01299.HK)$On October 20, 2,024,400 shares were repurchased at a cost of HK$135 million

$KUAISHOU-W (01024.HK)$On October 20, 2 million shares were repurchased at a cost of HK$114 million

$STANCHART (02888.HK)$On October 19, 1,868,400 shares were bought back at a cost of £13.757,500

$BEKE-W (02423.HK)$On October 19, 1.5 million shares were bought back at a cost of 7.472,500 US dollars

$HSBC HOLDINGS (00005.HK)$On October 19, 700,000 shares were repurchased at a cost of HK$42.7767 million

$ESR (01821.HK)$On October 20, 1.6 million shares were repurchased at a cost of HK$16.60.35 million

$YUM CHINA (09987.HK)$On October 19, 28,500 shares were bought back at a cost of 1.5 million US dollars

Editor/Somer